Literature DB >> 11929798

Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death.

Udo F Hartwig1, Michael Robbers, Claudia Wickenhauser, Christoph Huber.   

Abstract

Depletion of T lymphocytes from allogeneic bone marrow transplants successfully prevents the development of graft-versus-host disease (GvHD) but is associated with impaired engraftment, immunosuppression, and abrogation of the graft-versus-leukemia effect. We therefore explored the possibility of selectively eliminating alloreactive T cells by CD95/CD95L-mediated activation-induced cell death (AICD) in a major histocompatibility complex allogeneic murine model system. Activation of resting or preactivated T lymphocytes from C3H/HeJ (H-2(k)) mice was induced with irradiated BALB/cJ (H-2(d)) mouse-derived stimulators. Substantial decrease (> or = 80%) of proliferative and lytic responses by activated alloreactive T cells was subsequently achieved by incubating the mixed lymphocyte culture with an agonistic monoclonal antibody to CD95, and residual T cells recovered did not elicit alloreactivity upon challenge to H-2(d). Depletion of alloreactive T lymphocytes by AICD was specific because reactivity to an I-A(d)-restricted ovalbumin (OVA) peptide by OVA-specific CD4(+) T cells mixed into the allogeneic T-cell pool and subjected to induction of AICD in the absence of OVA peptide could be preserved. Adoptive transfer of donor-derived allogeneic T lymphocytes, depleted from alloreactive T cells by AICD in vitro, in the parent (C3H/He) to F(1) (C3H/He x BALB/c) GvHD model prevented lethal GvHD. The results presented suggest that alloreactive T cells can effectively be depleted from allogeneic T cells by induction of AICD to prevent GvHD and might introduce a new strategy for the separation of GvH-reactive T cells and T cells mediating antiviral and possibly graft-versus-leukemia effects.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11929798     DOI: 10.1182/blood.v99.8.3041

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation.

Authors:  Scott R Solomon; Stephan Mielke; Bipin N Savani; Aldemar Montero; Laura Wisch; Richard Childs; Nancy Hensel; John Schindler; Victor Ghetie; Susan F Leitman; Thao Mai; Charles S Carter; Roger Kurlander; Elizabeth J Read; Ellen S Vitetta; A John Barrett
Journal:  Blood       Date:  2005-04-07       Impact factor: 22.113

2.  Apoptotic signaling through Fas and TNF receptors ameliorates GVHD in mobilized peripheral blood grafts.

Authors:  K Mizrahi; I Yaniv; S Ash; J Stein; N Askenasy
Journal:  Bone Marrow Transplant       Date:  2014-02-24       Impact factor: 5.483

3.  Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease.

Authors:  Govindarajan Thangavelu; Jing Du; Katelyn G Paz; Michael Loschi; Michael C Zaiken; Ryan Flynn; Patricia A Taylor; Andrew Kemal Kirchmeier; Angela Panoskaltsis-Mortari; Leo Luznik; Kelli P MacDonald; Geoffrey R Hill; Ivan Maillard; David H Munn; Jonathan S Serody; William J Murphy; David Miklos; Corey S Cutler; John Koreth; Joseph H Antin; Robert J Soiffer; Jerome Ritz; Carol Dahlberg; Andrew T Miller; Bruce R Blazar
Journal:  Blood       Date:  2020-01-02       Impact factor: 22.113

4.  Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease.

Authors:  Stephan Mielke; Katayoun Rezvani; Bipin N Savani; Raquel Nunes; Agnes S M Yong; John Schindler; Roger Kurlander; Victor Ghetie; Elizabeth J Read; Scott R Solomon; Ellen S Vitetta; A John Barrett
Journal:  Blood       Date:  2007-05-03       Impact factor: 22.113

Review 5.  Immunotherapy of cancer: from vision to standard clinical practice.

Authors:  Christoph H Huber; Thomas Wölfel
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

6.  Role of activation-induced cell death in pathogenesis of patients with chronic hepatitis B.

Authors:  Chun-Sheng Hou; Gui-Qiang Wang; Shu-Lan Lu; Bei Yue; Ming-Rong Li; Xiao-Yan Wang; Jian-Wu Yu
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

7.  Selective reduction of graft-versus-host disease-mediating human T cells by ex vivo treatment with soluble Fas ligand.

Authors:  Osnat Bohana-Kashtan; Sebastien Morisot; Richard Hildreth; Cory Brayton; Hyam I Levitsky; Curt I Civin
Journal:  J Immunol       Date:  2009-06-17       Impact factor: 5.422

8.  A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique.

Authors:  Stephan Mielke; Raquel Nunes; Katayoun Rezvani; Vicki S Fellowes; Annie Venne; Scott R Solomon; Yong Fan; Emma Gostick; David A Price; Christian Scotto; Elizabeth J Read; A John Barrett
Journal:  Blood       Date:  2007-09-18       Impact factor: 22.113

9.  Differential role of ICAM ligands in determination of human memory T cell differentiation.

Authors:  Omar D Perez; Dennis Mitchell; Garry P Nolan
Journal:  BMC Immunol       Date:  2007-01-18       Impact factor: 3.615

Review 10.  Current status of haploidentical stem cell transplantation for leukemia.

Authors:  Xiao-jun Huang
Journal:  J Hematol Oncol       Date:  2008-12-31       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.